دورية أكاديمية
أعرض في EDS

Preclinical support for tumor protein D52 as a cancer vaccine antigen

التفاصيل البيبلوغرافية
العنوان: Preclinical support for tumor protein D52 as a cancer vaccine antigen
المؤلفون: Robert K. Bright
المصدر: Human Vaccines & Immunotherapeutics, Vol 19, Iss 3 (2023)
بيانات النشر: Taylor & Francis Group, 2023.
سنة النشر: 2023
المجموعة: LCC:Immunologic diseases. Allergy
LCC:Therapeutics. Pharmacology
مصطلحات موضوعية: TPD52 (D52), mD52 (murine orthologue TPD52), hD52 (human orthologue TPD52), overexpressed tumor-self antigen, oncogenic, shared, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950
الوصف: ABSTRACTOverexpressed tumor-associated antigens (TAAs) are a large group that includes proteins found at increased levels in tumors compared to healthy cells. Universal tumor expression can be defined as overexpression in all cancers examined as has been shown for Tumor Protein D52. TPD52 is an over expressed TAA actively involved in transformation, leading to increased proliferation and metastasis. TPD52 overexpression has been demonstrated in many human adult and pediatric malignancies. The murine orthologue of TPD52 (mD52) parallels normal tissue expression patterns and known functions of human TPD52 (hD52). Here in we present our preclinical studies over the past 15 years which have demonstrated that vaccine induced immunity against mD52 is effective against multiple cancers in murine models, without inducing autoimmunity against healthy tissues and cells.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 21645515
2164-554X
2164-5515
Relation: https://doaj.org/toc/2164-5515; https://doaj.org/toc/2164-554X
DOI: 10.1080/21645515.2023.2273699
URL الوصول: https://doaj.org/article/e3ae3616fe0541bb9eaa1bdea471b023
رقم الأكسشن: edsdoj.3ae3616fe0541bb9eaa1bdea471b023
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:21645515
2164554X
DOI:10.1080/21645515.2023.2273699